A Study to Investigate LDL-cholesterol Lowering With Inclisiran Compared to Bempedoic Acid in Patients With Atherosclerotic Cardiovascular Disease.

Inclusion Criteria:

1. Fasting LDL-C ≥ 70 mg/dL at screening

2. Participants must be on a stable (≥ 4 weeks) and well-tolerated lipid-loweringregimen (with or without Ezetimibe [10mg]) that must include a high-intensity statintherapy with either atorvastatin ≥40 mg QD or rosuvastatin ≥20 mg QD in a maximallytolerated or maximally approved dose at screening

3. Participants categorized as very high or high CV risk, as defined below:

• Very high risk participants with at least one of the following:

• Documented ASCVD: ACS: Unstable angina or myocardial infarction, Stableangina, Coronary revascularization, Unequivocally documented ASCVD uponprior imaging, Stroke and Transient Ischaemic Attack (TIA), Peripheralartery disease (PAD)

• Diabetes mellitus (DM) with target organ damage (defined asmicroalbuminuria, retinopathy, or neuropathy), or at least ≥ 3 major riskfactors, or early onset of Type 1 DM of long duration (< 20 years)

• A calculated SCORE2 ≥ 7.5 % for age < 50 years; SCORE2 ≥ 10 % for age 50-69 years; SCORE2-OP ≥ 15 % for age ≥ 70 years to estimate 10-year riskof fatal and non-fatal CVD

• Pre-existing diagnosis of heterozygous familial hyper-cholesterolemia (HeFH) with ASCVD or with another major risk factor OR

• High risk participants with at least one of the following:

• Markedly elevated single risk factors, in particular total cholesterol > 310 mg/dL, LDL-C > 190 mg/dL, or blood pressure ≥ 180/110 mmHg

• Pre-existing diagnosis of HeFH without other major risk factors

• DM without target organ damage (defined as microalbuminuria, retinopathy,or neuropathy), with DM duration ≥ 10 years or other additional riskfactor

• Moderate chronic kidney disease (eGFR 30-59 mL/min/1.73m2)

• A calculated SCORE2 2.5 to < 7.5 % for age < 50 years; SCORE2 5 to < 10 %for age 50-69 years; SCORE2-OP 7.5 to < 15 % for age ≥ 70 years toestimate 10-year risk of fatal and non-fatal CVD as defined by thecardiovascular risk categories in the 2019 ESC/EAS guideline (Mach et al 2020), and updated SCORE2 and SCORE2-OP (Hageman et al 2021, de Vries etal 2021, Visseren et al 2021). Further details for documented ASCVD willbe provided in the protocol.

4. Fasting triglyceride < 400 mg/dL at screening

Exclusion Criteria:

1. Acute coronary syndrome, ischemic stroke, peripheral arterial revascularizationprocedure or amputation due to atherosclerotic disease < 4 months prior to screeningvisit or V1.

2. Planned or expected cardiac, cerebrovascular or peripheral artery surgery orcoronary re-vascularization within 6 months after screening visit.

3. Heart failure NYHA class IV at screening or V1.

4. Participants on more than one other lipid-lowering drug on top of statin atscreening visit.

5. Previous treatment with a mAb directed towards PCSK9 (e.g., evolocumab, alirocumab)or planned use after screening visit.

6. Previous treatment prior to screening with BPA within 90 days

7. Previous exposure to Inclisiran or any other non-mAb PCSK9-targeted therapy, eitheras an investigational or marketed drug.